Get Your Personalized Supplement StackSupplement Stack Quiz

Bifidobacterium Breve Cgmcc 6402

Also known as: B. breve CGMCC 6402, B. breve, probiotic bacterium, Bifidobacterium breve CGMCC 6402

Overview

Bifidobacterium breve CGMCC 6402 is a specific strain of the anaerobic, gram-positive bacterium *Bifidobacterium breve*, which is naturally found in the human gastrointestinal tract, particularly in infants. This strain is utilized as a probiotic supplement primarily aimed at enhancing gut health, modulating immune function, and potentially influencing metabolic and neurological conditions. While *B. breve* as a species has been extensively studied, strain-specific research for CGMCC 6402 is less abundant. The evidence supporting its benefits varies, with some indications backed by randomized controlled trials and systematic reviews, while others require further validation. It is generally considered safe for most populations, with mild gastrointestinal side effects being the most common.

Benefits

Bifidobacterium breve CGMCC 6402, like other *B. breve* strains, shows promise in several areas. For gut health, it has been associated with improvements in constipation, diarrhea, and irritable bowel syndrome symptoms, including bowel movement frequency and stool consistency, though specific efficacy for CGMCC 6402 requires more direct research. The evidence for these gut health benefits is moderate, often derived from studies on various *B. breve* strains. In the context of neurodegenerative diseases such as Alzheimer's and Parkinson's, a systematic review suggests that *B. breve* may improve symptoms and reduce neuronal damage. However, this evidence is preliminary, largely based on animal models or small human studies, and not specific to the CGMCC 6402 strain. Conversely, a meta-analysis on *Bifidobacterium* species supplementation found no significant effect on fasting blood glucose or HbA1c, indicating limited impact on glycemic control. The strength of evidence for metabolic benefits is low, and for neurodegenerative benefits, it is emerging but not yet conclusive for human application.

How it works

Bifidobacterium breve CGMCC 6402 exerts its effects primarily within the gastrointestinal tract. It modulates the gut microbiota by fermenting various carbohydrates, such as mannitol and sorbitol. This fermentation process produces short-chain fatty acids (SCFAs), which are crucial for maintaining the integrity of the gut barrier and influencing immune responses. The bacterium may also interact directly with the host's immune system, contributing to reduced inflammation and enhanced mucosal defenses. In the context of neurodegenerative diseases, *B. breve* is hypothesized to influence the gut-brain axis, potentially mitigating neuroinflammation and neuronal damage. As a live probiotic, its action is local within the gut, and systemic absorption is not a relevant mechanism.

Side effects

Bifidobacterium breve CGMCC 6402 is generally well-tolerated and considered likely safe for most individuals when taken orally for up to one year. The most common side effects are mild gastrointestinal symptoms, such as gas and bloating, which occur in less than 5% of users. These symptoms are typically transient and resolve with continued use or dosage adjustment. However, rare but serious adverse events have been reported, particularly in vulnerable populations. There have been isolated cases of bloodstream infections (bacteremia) in immunocompromised individuals or infants with intestinal blockages or other severe underlying conditions. Therefore, caution is advised for these groups, and medical supervision is recommended. No significant drug interactions have been reported with *B. breve*. Pregnant and breastfeeding individuals should consult a healthcare professional before use due to limited specific safety data in these populations. Individuals with compromised immune systems or severe intestinal issues should avoid this supplement unless specifically advised by a doctor.

Dosage

Specific dosing guidelines for *Bifidobacterium breve* CGMCC 6402 are not well-established in the scientific literature. However, general *B. breve* probiotic doses used in clinical trials typically range from 10^8 to 10^10 Colony Forming Units (CFU) per day. The duration of supplementation in studies varies considerably, often ranging from 4 to 12 weeks, but can extend to several months depending on the intended outcome. There are no standardized recommendations regarding the optimal timing of intake relative to meals or the specific formulation (e.g., capsules, powders) for CGMCC 6402 to ensure maximum viability and efficacy. It is important to follow the manufacturer's instructions for any specific product containing this strain. Due to the lack of strain-specific data, upper limits and safety thresholds for CGMCC 6402 are not precisely defined, but the general safety profile of *B. breve* suggests a wide therapeutic window.

FAQs

Is B. breve CGMCC 6402 effective for blood sugar control?

Current meta-analyses on *Bifidobacterium* supplementation, while not specific to CGMCC 6402, indicate no significant benefit for fasting blood glucose or HbA1c levels in humans.

Is B. breve CGMCC 6402 safe for children?

It is likely safe for most children, but caution is advised for premature infants or those with existing intestinal issues due to rare risks of infection in vulnerable populations.

How soon can benefits be expected from B. breve CGMCC 6402?

Clinical effects on gut health may become noticeable within a few weeks of consistent use. Potential neurological or metabolic benefits, if any, would likely require longer-term supplementation and study.

Can B. breve CGMCC 6402 cause infections?

While generally safe, there are rare reports of bloodstream infections in highly vulnerable individuals, such as those who are severely immunocompromised or infants with intestinal blockages.

Research Sources

https://pmc.ncbi.nlm.nih.gov/articles/PMC10831893/ – This systematic review and meta-analysis of 6 RCTs, involving 781 subjects, investigated the effect of *Bifidobacterium* species on glycemic control. It concluded that *Bifidobacterium* supplementation had no significant effect on fasting blood glucose or HbA1c, indicating limited metabolic benefits for blood sugar regulation. The study's methodology was robust, but it did not specifically analyze the CGMCC 6402 strain.
https://www.webmd.com/vitamins/ai/ingredientmono-1665/bifidobacterium-breve – This source provides a summary of clinical safety data for *Bifidobacterium breve*. It indicates that the supplement is generally safe for most populations when taken orally for up to one year, with mild gastrointestinal side effects being common. It also highlights rare instances of bloodstream infections in immunocompromised individuals or infants with intestinal complications, serving as a comprehensive safety overview.
https://pubmed.ncbi.nlm.nih.gov/39940249/ – This systematic review, published in January 2025, explored the potential of *B. breve* in neurodegenerative diseases like Alzheimer's and Parkinson's. It suggests that *B. breve* may improve symptoms and reduce neuronal damage, based on mixed human and animal studies. While promising, the evidence is largely preclinical or from small human trials, indicating an emerging but not yet conclusive role for *B. breve* in this area.